Lopid (gemfibrozil) Disease Interactions
There are 5 disease interactions with Lopid (gemfibrozil):
Fibric Acid Derivatives (Includes Lopid) ↔ Biliary Cirrhosis
Severe Potential Hazard, High plausibility
Applies to: Biliary Cirrhosis
The use of fibric acid derivatives is contraindicated in patients with primary biliary cirrhosis. These agents may further raise the already elevated cholesterol in these patients.
Fibric Acid Derivatives (Includes Lopid) ↔ Cholelithiasis
Severe Potential Hazard, High plausibility
Applies to: Gallbladder Disease
The use of fibric acid derivatives is contraindicated in patients with gallbladder disease. A significantly increased incidence of cholelithiasis has been observed in patients treated with the fibric acid derivative, clofibrate, presumably because of increased cholesterol excretion into the bile. Based on two separate studies (the WHO study and the Coronary Drug Project study), clofibrate use was associated with twice the risk of developing cholelithiasis and cholecystitis requiring surgery. Due to their structural and pharmacologic similarities, use of other fibric acid derivatives may be expected to carry the same risk.
Fibric Acid Derivatives (Includes Lopid) ↔ Rhabdomyolysis
Severe Potential Hazard, Moderate plausibility
Applies to: Myoneural Disorder, Myopathy
Severe myopathy, including rhabdomyolysis with acute renal failure secondary to myoglobinuria, has been reported rarely with the use of fibric acid derivatives. The myopathy may be dose-related and is characterized by muscle aches and/or weakness in conjunction with increases in creatine phosphokinase (CPK) values exceeding 10 times the upper limit of normal. Therapy with fibric acid derivatives should be administered cautiously in patients with preexisting myopathy or a myoneural disorder, since it may delay the recognition or confound the diagnosis of a drug-induced musculoskeletal effect. Patients should be advised to report promptly any unusual muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever. Periodic CPK determinations may be considered in some patients, although the value of such monitoring is uncertain. Therapy should be withdrawn if markedly elevated CPK levels occur or if drug-related myopathy is diagnosed or suspected.
Gemfibrozil (Includes Lopid) ↔ Liver Disease
Severe Potential Hazard, High plausibility
Applies to: Liver Disease
The use of gemfibrozil is considered by the manufacturer to be contraindicated in patients with hepatic impairment. Gemfibrozil is primarily metabolized by the liver. Decreased drug metabolism may lead to accumulation and increased risk of toxicity, including biochemical abnormalities of liver function and musculoskeletal adverse effects. Therapy with gemfibrozil should be administered cautiously in patients with active liver disease. Liver function tests, including serum transaminase levels, should be performed periodically. Therapy should be withdrawn if persistent abnormalities occur and are thought to be related to the drug.
Gemfibrozil (Includes Lopid) ↔ Renal Dysfunction
Severe Potential Hazard, High plausibility
Applies to: Renal Dysfunction
The use of gemfibrozil is considered by the manufacturer to be contraindicated in patients with severely impaired renal function. The rate of clearance of gemfibrozil may be decreased in such patients, with possible accumulation during chronic dosing. Increased adverse effects, including rhabdomyolysis (with or without secondary renal failure) and severe hyperkalemia, have been associated with the use of fibric acid derivatives in patients with renal insufficiency. Some patients, usually those with baseline plasma creatinine above 2.0 mg/dL, have also experienced a deterioration of renal function when treated with gemfibrozil. Therapy with gemfibrozil should be administered cautiously in patients with significant renal impairment. Reduced dosages and close clinical monitoring are recommended.
You should also know about...
Lopid (gemfibrozil) drug Interactions
There are 75 drug interactions with Lopid (gemfibrozil)
See also...
Drug Interaction Classification
The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
| Major | Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. |
| Moderate | Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. |
| Minor | Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. |
Do not stop taking any medications without consulting your healthcare provider.
Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. Multum's drug information does not endorse drugs, diagnose patients, or recommend therapy. Multum's drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2012 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.
